The High Throughput Screening Shared Resource allows members of the Cancer Center to use the techniques of high-throughput screening (HTS) of compounds or genomic siRNA libraries. The HTS laboratory provides target assessment and assay evaluation, assay development and testing, screening of chemical compounds or siRNA libraries, data analysis and storage, and "hit" validation. To gain access to the HTS facility, Cancer Center members must have a project evaluated by the Cancer Center HTS Oversight Committee, which will assess both the practicality and the scientific and therapeutic value of targets for screening. For approved projects, the HTS staff will then assess the cost and practicality of the proposed assay and work with the initiating laboratory to develop the assay into a form suitable for HTS that reproducibly achieves the desired signal to noise statistics. The HTS laboratory works to minimize the cost of the experiment, which often requires changing reagents and sometimes completely redesigning the assay. Once an assay has an acceptable signal to noise ratio in small scale experiments, for compound screens multiple assay plates are treated with DMSO (the compound diluent) to determine reproducibility under conditions similar to HTS screening and then are screened against a test compound library to determine the "hit" rate. Genomic siRNA experiments are developed in a similar manner, except that they are run in 96 well format in replicate plates and no test library is used before the genomic screen is begun. Just as with compounds, siRNA experimental controls must achieve a reproducible signal to background ratio in runs of multiple plates before the project is allowed to screen the genomic library.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA142543-04
Application #
8519961
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$73,129
Indirect Cost
$27,467
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wong, Mandy S; Wright, Woodring E; Shay, Jerry W (2014) Alternative splicing regulation of telomerase: a new paradigm? Trends Genet 30:430-8
Chau, Vincent; Lim, S Kyun; Mo, Wei et al. (2014) Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer Res 74:586-97
Iscla, Irene; Wray, Robin; Wei, Shuguang et al. (2014) Streptomycin potency is dependent on MscL channel expression. Nat Commun 5:4891
Fu, Peng; Johnson, Melissa; Chen, Hong et al. (2014) Carpatamides A-C, cytotoxic arylamine derivatives from a marine-derived Streptomyces sp. J Nat Prod 77:1245-8
Park, Jason Y; Gunpat, Joshua; Liu, Li et al. (2014) Red-shifted emission from 1,2-dioxetane-based chemiluminescent reactions. Luminescence 29:553-8
Gerber, David E; Laccetti, Andrew L; Xuan, Lei et al. (2014) Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst 106:
Yang, Liu; Kwon, Junghee; Popov, Yury et al. (2014) Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 146:1339-50.e1
Li, Biaoru; Ding, Lianghao; Yang, Chinrang et al. (2014) Characterization of transcription factor networks involved in umbilical cord blood CD34+ stem cells-derived erythropoiesis. PLoS One 9:e107133
Ludlow, Andrew T; Robin, Jerome D; Sayed, Mohammed et al. (2014) Quantitative telomerase enzyme activity determination using droplet digital PCR with single cell resolution. Nucleic Acids Res 42:e104
King, Kelly A; Gordon-Salant, Sandra; Pawlowski, Karen S et al. (2014) Hearing loss is an early consequence of Npc1 gene deletion in the mouse model of Niemann-Pick disease, type C. J Assoc Res Otolaryngol 15:529-41

Showing the most recent 10 out of 83 publications